227 related articles for article (PubMed ID: 35238004)
1. Positron Emission Tomography in Atherosclerosis Research.
Roivainen A; Ståhle M; Saraste A
Methods Mol Biol; 2022; 2419():825-839. PubMed ID: 35238004
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe.
Ahmed M; Tegnebratt T; Tran TA; Lu L; Damberg P; Gisterå A; Tarnawski L; Bone D; Hedin U; Eriksson P; Holmin S; Gustafsson B; Caidahl K
Int J Nanomedicine; 2020; 15():6137-6152. PubMed ID: 32884268
[TBL] [Abstract][Full Text] [Related]
3. [¹⁸F]-fluorodeoxyglucose PET imaging of atherosclerosis.
Blomberg BA; Høilund-Carlsen PF
PET Clin; 2015 Jan; 10(1):1-7. PubMed ID: 25455876
[TBL] [Abstract][Full Text] [Related]
4. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see.
Cocker MS; Mc Ardle B; Spence JD; Lum C; Hammond RR; Ongaro DC; McDonald MA; Dekemp RA; Tardif JC; Beanlands RS
J Nucl Cardiol; 2012 Dec; 19(6):1211-25. PubMed ID: 23073913
[TBL] [Abstract][Full Text] [Related]
5. Vascular imaging with 18F-FDG PET/CT: optimal 18F-FDG circulation time?
Rudd JH; Elkhawad M; Fayad ZA
J Nucl Med; 2009 Sep; 50(9):1560; author reply 1560-1. PubMed ID: 19690022
[No Abstract] [Full Text] [Related]
6. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography.
Miller PW; Long NJ; Vilar R; Gee AD
Angew Chem Int Ed Engl; 2008; 47(47):8998-9033. PubMed ID: 18988199
[TBL] [Abstract][Full Text] [Related]
7. In Vivo ¹⁸F-FDG-PET Imaging in Mouse Atherosclerosis.
Mateo J; Bilbao I; Vaquero JJ; Ruiz-Cabello J; España S
Methods Mol Biol; 2015; 1339():377-86. PubMed ID: 26445805
[TBL] [Abstract][Full Text] [Related]
8. Imaging atherosclerosis with positron emission tomography.
Joseph P; Tawakol A
Eur Heart J; 2016 Oct; 37(39):2974-2980. PubMed ID: 27125951
[TBL] [Abstract][Full Text] [Related]
9. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement.
Huet P; Burg S; Le Guludec D; Hyafil F; Buvat I
J Nucl Med; 2015 Apr; 56(4):552-9. PubMed ID: 25722452
[TBL] [Abstract][Full Text] [Related]
10. Analysis of
Nogales P; Velasco C; Mota-Cobián A; González-Cintado L; Mota RA; España S; Mateo J; Bentzon JF
Arterioscler Thromb Vasc Biol; 2021 Oct; 41(10):e480-e490. PubMed ID: 34289703
[TBL] [Abstract][Full Text] [Related]
11. Exploring the nature of atheroma and cardiovascular inflammation in vivo using positron emission tomography (PET).
Buscombe JR
Br J Radiol; 2015 Sep; 88(1053):20140648. PubMed ID: 26110339
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of atherosclerotic lesions by positron emission tomography - can it meet the expectations?
Brammen L; Steiner S; Berent R; Sinzinger H
Vasa; 2016; 45(2):125-32. PubMed ID: 27058798
[TBL] [Abstract][Full Text] [Related]
13. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis Burdens in Diabetes Mellitus: Assessment by PET Imaging.
Høilund-Carlsen PF; Piri R; Madsen PL; Revheim ME; Werner TJ; Alavi A; Gerke O; Sturek M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142181
[TBL] [Abstract][Full Text] [Related]
15. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study.
Rudd JH; Myers KS; Bansilal S; Machac J; Woodward M; Fuster V; Farkouh ME; Fayad ZA
Circ Cardiovasc Imaging; 2009 Mar; 2(2):107-15. PubMed ID: 19808576
[TBL] [Abstract][Full Text] [Related]
16. Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by
Li X; Heber D; Cal-Gonzalez J; Karanikas G; Mayerhoefer ME; Rasul S; Beitzke D; Zhang X; Agis H; Mitterhauser M; Wadsak W; Beyer T; Loewe C; Hacker M
J Nucl Med; 2017 Jun; 58(6):968-974. PubMed ID: 28232606
[No Abstract] [Full Text] [Related]
17. The next generation of positron emission tomography radiopharmaceuticals in oncology.
Rice SL; Roney CA; Daumar P; Lewis JS
Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
[TBL] [Abstract][Full Text] [Related]
18. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
19. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG in distinction of atherosclerotic plaque: Innovation in PET/MRI technology.
Benedetto R; Carneiro MP; Junqueira FA; Coutinho A; von Ristow A; Fonseca LM
Arq Bras Cardiol; 2009 Dec; 93(6):e84-7, e97-100. PubMed ID: 20379625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
